Prostate Cancer Trial, Recruiting NCT06236789 Sponsor: Yonsei University Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT06236789
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults who are male and aged 19 years or older
  • People who have been diagnosed with prostate cancer confirmed by a tissue sample (biopsy)
  • People whose prostate cancer has continued to grow despite hormone-reducing treatment (known as castration-resistant prostate cancer)
  • People whose general health and ability to carry out daily activities meets a certain minimum level, as rated by a standard medical scale (ECOG score of 2 or less — confirm with trial site)
  • People who have previously been treated with a chemotherapy drug called docetaxel
  • People who have a recent PSA (prostate-specific antigen) blood test result available
  • People whose cancer can be measured or assessed using standard imaging guidelines (confirm with trial site)

Who may not be able to join:

  • People who have been diagnosed with another type of cancer within the past 3 years (other than prostate cancer)
  • People who have had an organ transplant at any point in the past
  • People whose prostate cancer still responds to standard hormone-reducing treatment (hormone-sensitive prostate cancer)
  • People whose general health falls below a certain level on the standard medical rating scale (ECOG score of 3 or higher — confirm with trial site)
  • People who have not previously been treated with docetaxel
  • People who have previously been treated with a chemotherapy drug called ifosfamide
  • People who do not have a PSA blood test result available
  • People whose cancer cannot be measured or assessed using standard imaging guidelines (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Sang Joon Shin, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine

Phone: 82-2-2228-8130

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 November 2016
Est. completion
1 November 2026

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Objective response rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov